ICON plc | Clinical Research Organisation (CRO) for Drug Development

The Role of ICER as an Independent HTA Organisation

Primary research evaluating ICER’s influence over payers and manufactures

Personalising Digital Health Solutions

Digital health solutions for clinical R&D efficiency and patient outcomes

Making Sense of the Biosimilars Market

Insights you need for successful biosimilar commercialisation

Key Considerations in Chronic Pain Clinical Trials

Determine the right design, assessments and endpoints in your pain study

ICON Insights

23 May 2019

The Digitization of Clinical Drug Development

Dr. Uma Arumugam takes a look at the advancements in digital applications and technology impacting clinical drug development.

18 May 2019

Biosimilar Development in Ophthalmology

ICON experts Bart Chapman and Shanthi Sundaramoorthy answer common questions about ophthalmology studies, and those relating to biosimilars.

17 May 2019

Using Economic Models to Gain Early Access

Early access schemes demand new ways of performing health economic evaluations.

09 May 2019

How Value-Based Healthcare affects Medical Device Development

Manufacturers need to employ new methods and tools to maximise the effectiveness of their efforts in bringing new devices to market.

24 April 2019

5 Common Barriers to Harmonised Real World Data

Learn 5 common barriers to Real World Data (RWD) harmonisation and insights on how to overcome these challenges.

16 April 2019

ePharma IMPACT 2019 Recap

ICON's Travis Tingey attended the recent ePharma IMPACT conference and shares his thoughts on notable trends and themes.

15 April 2019

Reflections from MAPS Conference 2019

ICON Medical Communications attended the 2019 MAPS Annual Meeting and share key themes and trends.

15 April 2019

AMCP Annual Meeting 2019 Recap

Key topics and trends covered at the AMCP 2019 Annual Meeting.

11 April 2019

Accelerating Drug Development for Patients with Rare Diseases

CROs can help to create more patient-centric trials placing the patients’ needs and day to day life as the highest priority in protocol and operational design.

Services

Therapeutics

Innovation

Insights

News & Events

About ICON

ICON announces the acquisition of MeDiNova Research

Site & Patient Solutions

MDR/IVDR brings higher costs and bottlenecks

Drug Safety Reporting

The Impact of AI on Outcomes Based Contracting